Zhang Shuishen, Jia Minghan, Cai Xiaoli, Yang Weixiong, Liao Shufen, Liu Zhenguo, Wen Jing, Luo Kongjia, Cheng Chao
Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Breast Cancer, Guangdong Provincial People's Hospital Cancer Center, Guangdong Academy of Medical Sciences, Guangzhou, China.
Front Oncol. 2020 Dec 18;10:586084. doi: 10.3389/fonc.2020.586084. eCollection 2020.
The prognostic value of ABO blood types is not well clarified for esophageal carcinoma (EC). This study attempted to elucidate the associations between different ABO blood types and disease-free survival (DFS) and overall survival (OS) of EC.
This study was a retrospective review of the records of 2179 patients with EC who received surgery from December 2000 to December 2008. The prognostic impact of ABO blood group on DFS and OS were estimated using the Kaplan-Meier method and cox proportional hazard models.
Univariate analyses found significant differences in DFS and OS among the four blood types. Multivariate analyses showed ABO blood type independently predicted DFS (=0.001) and OS (=0.002). Furthermore, patients with non-B blood types had a significantly shorter DFS (HR=1.22, 95%CI:1.07-1.38, =0.002) and OS (HR=1.22, 95%CI:1.07-1.38, =0.003) than patients with blood type B, and patients with non-O blood types had a significantly better DFS (HR=0.86, 95%CI:0.77-0.96, =0.006) and OS (HR=0.86, 95%CI:0.77-0.96, =0.007) than patients with blood type O. Subgroup analyses found that blood type B had a better DFS and OS than non-B in patients who were male, younger, early pathological stages and had squamous-cell carcinomas (ESCC). Blood type O had a worse DFS and OS than non-O in patients who were male, younger, and had ESCC (<0.05).
The results demonstrate that ABO blood group is an independent prognostic factor of survival, and that type B predicts a favorable prognosis, whereas type O predicts an unfavorable prognosis for survival in patients with EC, especially those with ESCC.
ABO血型对食管癌（EC）的预后价值尚未完全明确。本研究旨在阐明不同ABO血型与EC患者无病生存期（DFS）和总生存期（OS）之间的关联。
本研究对2000年12月至2008年12月期间接受手术的2179例EC患者的记录进行了回顾性分析。采用Kaplan-Meier法和Cox比例风险模型评估ABO血型对DFS和OS的预后影响。
单因素分析发现四种血型的DFS和OS存在显著差异。多因素分析显示ABO血型独立预测DFS（=0.001）和OS（=0.002）。此外，非B血型患者的DFS（HR=1.22，95%CI：1.07-1.38，=0.002）和OS（HR=1.22，95%CI：1.07-1.38，=0.003）显著短于B血型患者，非O血型患者的DFS（HR=0.86，95%CI：0.77-0.96，=0.006）和OS（HR=0.86，95%CI：0.77-0.96，=0.007）显著优于O血型患者。亚组分析发现，在男性、年轻、病理分期早且患有鳞状细胞癌（ESCC）的患者中，B血型的DFS和OS优于非B血型。在男性、年轻且患有ESCC的患者中，O血型的DFS和OS比非O血型差（<0.05）。
结果表明，ABO血型是生存的独立预后因素，B型预示着良好的预后，而O型预示着EC患者，尤其是ESCC患者生存预后不良。
